Royce & Associates’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.69M | Sell |
25,757
-4,500
| -15% | -$470K | 0.03% | 559 |
|
|
2025
Q1 | $3.53M | Sell |
30,257
-6,743
| -18% | -$786K | 0.04% | 498 |
|
|
2024
Q4 | $3.13M | Buy |
37,000
+14,500
| +64% | +$1.23M | 0.03% | 559 |
|
|
2024
Q3 | $2.02M | Buy |
22,500
+9,500
| +73% | +$854K | 0.02% | 620 |
|
|
2024
Q2 | $1.05M | Hold |
13,000
| – | – | 0.01% | 715 |
|
|
2024
Q1 | $1.04M | Buy |
+13,000
| New | +$1.04M | 0.01% | 721 |
|
|
2021
Q3 | – | Sell |
-20,300
| Closed | -$1.37M | – | 985 |
|
|
2021
Q2 | $1.37M | Sell |
20,300
-5,400
| -21% | -$364K | 0.01% | 813 |
|
|
2021
Q1 | $1.46M | Hold |
25,700
| – | – | 0.01% | 803 |
|
|
2020
Q4 | $2.09M | Hold |
25,700
| – | – | 0.02% | 715 |
|
|
2020
Q3 | $1.83M | Hold |
25,700
| – | – | 0.02% | 694 |
|
|
2020
Q2 | $2.12M | Sell |
25,700
-14,400
| -36% | -$1.19M | 0.02% | 656 |
|
|
2020
Q1 | $2.36M | Sell |
40,100
-20,000
| -33% | -$1.18M | 0.03% | 559 |
|
|
2019
Q4 | $6.21M | Sell |
60,100
-44,600
| -43% | -$4.61M | 0.06% | 436 |
|
|
2019
Q3 | $2.12M | Sell |
104,700
-10,000
| -9% | -$202K | 0.02% | 696 |
|
|
2019
Q2 | $2.95M | Sell |
114,700
-67,700
| -37% | -$1.74M | 0.03% | 624 |
|
|
2019
Q1 | $2.6M | Sell |
182,400
-150,000
| -45% | -$2.13M | 0.02% | 665 |
|
|
2018
Q4 | $937K | Hold |
332,400
| – | – | 0.01% | 871 |
|
|
2018
Q3 | $1.15M | Sell |
332,400
-556,000
| -63% | -$1.92M | 0.01% | 899 |
|
|
2018
Q2 | $2.84M | Sell |
888,400
-67,600
| -7% | -$216K | 0.02% | 751 |
|
|
2018
Q1 | $2.34M | Buy |
956,000
+75,000
| +9% | +$184K | 0.02% | 807 |
|
|
2017
Q4 | $4.93M | Hold |
881,000
| – | – | 0.03% | 590 |
|
|
2017
Q3 | $4.89M | Hold |
881,000
| – | – | 0.03% | 576 |
|
|
2017
Q2 | $4.85M | Hold |
881,000
| – | – | 0.03% | 597 |
|
|
2017
Q1 | $3.44M | Buy |
+881,000
| New | +$3.44M | 0.02% | 705 |
|